ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Jessica S. Donington
Daniel L. Miller
Mark S. Allen
Claude Deschamps
Francis C. Nichols, III
Peter C. Pairolero
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Donington, J. S.
Right arrow Articles by Pairolero, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Donington, J. S.
Right arrow Articles by Pairolero, P. C.
Related Collections
Right arrow Esophagus - cancer

Ann Thorac Surg 2004;77:1193-1199
© 2004 The Society of Thoracic Surgeons


Original article: general thoracic

Preoperative chemoradiation therapy does not improve early survival after esophagectomy for patients with clinical stage III adenocarcinoma of the esophagus

Jessica S. Donington, MDa, Daniel L. Miller, MDa*, Mark S. Allen, MDa, Claude Deschamps, MDa, Francis C. Nichols, III, MDa, Peter C. Pairolero, MDa

a Division of General Thoracic Surgery, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA

Accepted for publication September 4, 2003.

* Address reprint requests to Dr Miller, Section of General Thoracic Surgery, Emory University Clinic, 1365 Clifton Rd NE, Atlanta, GA 30322, USA
e-mail: daniel_miller{at}emoryhealthcare.org

Presented at the Forty-ninth Annual Meeting of the Southern Thoracic Surgical Association, Miami Beach, FL, Nov 7–9, 2002.

BACKGROUND: The optimal treatment for locally advanced esophageal cancer remains controversial. The objective of this study was to determine if preoperative chemoradiation therapy (P-CRT) followed by esophagectomy for patients with clinical stage III adenocarcinoma of the esophagus offered any survival advantage as compared with esophagectomy alone.

METHODS: Between January 1998 and June 2001, 75 nonrandomized patients with clinical stage III adenocarcinoma of the esophagus underwent either P-CRT and esophagectomy or esophagectomy alone. All patients were staged before initiation of treatment with computed tomography and endoscopic ultrasound.

RESULTS: P-CRT followed by esophagectomy was performed in 47 patients (63%) and esophagectomy alone in 28 patients (37%). Although the P-CRT group was younger (median age, 61 years versus 67 years), the two groups were otherwise similar for gender, comorbidities, and symptoms. Overall operative mortality was 4%. Follow-up was complete in all patients and ranged from 5 to 40 months (median, 20 months). Overall, one-, two-, and three-year survivals were 72%, 44%, and 42%, respectively. Three-year survival was identical (42%) for both the P-CRT and surgery alone patients (p = 0.70). Three-year disease-free survival for the P-CRT group was 29% as compared with 33% for the surgery only group (p = 0.51).

CONCLUSIONS: Patients with clinical stage III adenocarcinoma of the esophagus do not appear to gain an early overall or disease-free survival advantage when treated with P-CRT followed by surgery as compared with surgery alone. However, long-term follow-up is needed. A large, prospective, randomized trial is warranted to address the question of whether P-CRT offers any survival benefit or impact on pattern of recurrence in patients undergoing esophagectomy for locally advanced disease.




This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
J. M. Donahue, F. C. Nichols, Z. Li, D. A. Schomas, M. S. Allen, S. D. Cassivi, A. Jatoi, R. C. Miller, D. A. Wigle, K. R. Shen, et al.
Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival.
Ann. Thorac. Surg., February 1, 2009; 87(2): 392 - 398.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. D. Luu, P. Gaur, S. D. Force, C. A. Staley, K. A. Mansour, J. I. Miller Jr, and D. L. Miller
Neoadjuvant Chemoradiation Versus Chemotherapy for Patients Undergoing Esophagectomy for Esophageal Cancer
Ann. Thorac. Surg., April 1, 2008; 85(4): 1217 - 1224.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2004 by The Society of Thoracic Surgeons.